Integrative Medicine treated 22 patients with juvenile ankylosing spondylitis_0.docVIP

 PAGE \* MERGEFORMAT 7 Integrative Medicine treated 22 patients with juvenile ankylosing spondylitis OF: Package power, Xu Xinyu, Zhuo Ying, Liu Yuemin [Keywords:] in ankylosing spondylitis, Chinese and Western medicine, Chinese medicine fumigation treatments Ankylosing spondylitis (AS) is a chronic progressive, chronic inflammation of joints to the main axis of the systemic disease, a certain disability. The peak age 20 to 30 years old, 16 cases before the age of onset called juvenile ankylosing spondylitis (JAS). JAS AS compared the clinical performance and have different characteristics, clinical prone to cause misdiagnosis and missed diagnosis. JAS 22 admitted to hospital in recent years, cases, now in its clinical features and results of Integrative Medicine reported below. 1 Clinical data 2001-2007 22 cases were hospital inpatients, 17 males and 5 females, aged 8 to 16 years old, average age 12.7 years, the shortest duration of 10 d, up to 4 years, an average of 1.1 years patients were .22 meet the 1984 modified New York criteria AS [1]. TCM is blocking network card 10 cases of heat, cold resistance network card in 12 cases. JAS patients were 22 patients with chronic onset, the first symptom of lumbosacral pain for the 6 cases, 5 cases of knee pain, heel pain, knee-ankle in 5 cases, 4 cases of hip pain, a few months to several years after the beginning of a sense of the waist sacral pain, there is always the course of 2 patients had no lumbosacral pain, only the hip and groin pain complaints. the course of fever in 10 cases, body temperaturegt; 39 ℃ in 4 cases, “4” test was positive in 17 cases , can not be completed because of pain in 3 patients, sacroiliac joint tenderness positive in 18 cases, 7 cases of positive heel tenderness, limitation of activity in 9 patients waist and forced to stay in bed and not actors in 7 cases .22 cases, HLA-B27 positive in 18 cases, erythrocyte sedimentation rate (ESR) increased in 15 cases, C-reactive p